AGTC to Host Virtual R&D Day on July 22, 2021
July 08 2021 - 7:00AM
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a
biotechnology company conducting human clinical trials of
adeno-associated virus (AAV)-based gene therapies for the treatment
of rare retinal diseases, today announced that it will host a
virtual R&D Day from 10:00 am to 1:00 pm ET on Thursday, July
22, 2021.
AGTC’s R&D Day will include a review of
12-month data from the highest dose groups in the ongoing Phase 1/2
clinical trials in X-linked retinitis pigmentosa (XLRP), which the
Company announced in May, and expanded analysis of the recently
reported data from the Company’s ongoing Phase 1/2 clinical trial
in achromatopsia (ACHM). The event also will include a discussion
on light sensitivity and achromatopsia genetics, and an overview of
the Company’s manufacturing capabilities, including the 21,000
square foot current Good Manufacturing Practices (cGMP)
manufacturing and quality control facility being built in
Florida.
“AGTC has seen highly encouraging 12-month data
from our XLRP and ACHM clinical trials over the last two months,
which gives us confidence in our abilities to execute the clinical
and regulatory steps necessary to advance those therapies,” said
Sue Washer, President and Chief Executive Officer of AGTC. “We look
forward to taking a deeper dive into this data during our R&D
Day and discussing preparations for late-stage development of our
ACHM and XLRP candidates.”
AGTC R&D Day Agenda:
- Corporate Overview
- Sue Washer, President & Chief Executive Officer
- Pre-Clinical Pipeline
- Adrian Timmers, Executive Director, In vivo Pharmacology and
Toxicology
- Manufacturing and New Facility Update
- Dave Knop, PhD, Vice President of Process Development
- Stephen Potter, Chief Business Officer
- XLRP Indication, Phase 1/2 Data
- Robert Sisk, MD – Associate Professor of
Ophthalmology, University of
Cincinnati and Cincinnati Eye Institute, XLRP Phase 1/2
clinical trial investigator
- ACHM Indication, Phase 1/2 Data
- Rachel Huckfeldt, MD, PhD, Assistant Professor of
Ophthalmology, Harvard Medical School Department of Ophthalmology,
Director, Inherited Retinal Degenerations Fellowship,
Massachusetts Eye and Ear Infirmary
- Light Sensitivity and Achromatopsia Genetics
- Joseph Carroll, PhD – Richard O. Schultz, MD / Ruth Works
Professor of Ophthalmology Professor of Ophthalmology & Visual
Sciences, Biophysics, and Cell Biology, Neurobiology and Anatomy
Director, Advanced Ocular Imaging Program
A live audio webcast of the presentation with accompanying
slides can be accessible by
visiting ir.agtc.com/events-and-presentations. Please log in
approximately 10 minutes prior to the scheduled start
time.
Those interested in attending can RSVP by
clicking the RSVP link in the Events & Presentations page of
the investor section at AGTC.com.
The archived webcast and slide presentation will
be available in the Events and Presentations section of the
Company's website.
About AGTCAGTC is a
clinical-stage biotechnology company developing genetic therapies
for people with rare and debilitating ophthalmic, otologic and
central nervous system (CNS) diseases. AGTC is a leader in
designing and constructing all critical gene therapy elements and
bringing them together to develop customized therapies that address
real patient needs. AGTC’s most advanced clinical programs leverage
its best-in-class technology platform to potentially improve vision
for patients with an inherited retinal disease. AGTC has active
clinical trials in X-linked retinitis pigmentosa (XLRP) and
achromatopsia (ACHM B3 and ACHM A3). Its preclinical programs build
on the Company’s industry leading AAV manufacturing technology and
scientific expertise. AGTC is advancing multiple important pipeline
candidates to address substantial unmet clinical need in
optogenetics, otology and CNS disorders. In recent years AGTC has
entered into strategic partnerships with companies including
Otonomy, Inc., a biopharmaceutical company dedicated to the
development of innovative therapeutics for neurotology, and Bionic
Sight, LLC, an innovator in the emerging field of optogenetics and
retinal coding.
IR/PR CONTACTS:David Carey (IR) or Glenn Silver
(PR)Lazar FINN PartnersT: (212) 867-1768 or (646)
871-8485david.carey@finnpartners.com or
glenn.silver@finnpartners.com
Corporate Contact:Stephen PotterChief Business
OfficerApplied Genetic Technologies CorporationT: (617)
413-2754spotter@agtc.com
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Apr 2023 to Apr 2024